BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the selection of ...
Incyte (Nasdaq: INCY) reported strong early-stage clinical results for an experimental precision antibody that sharply reduced disease markers in patients with essential thrombocythemia, bolstering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback